step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Efficacy and safety of once-weekly 2·4 versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 Phase 3 Trial of Semaglutide

Obesity is an escalating global epidemic, impacting nearly 40 percent of U.S

Continue your semaglutide unless your doctor advises otherwise

Peptide therapy for weight loss can be a game-changer for those who: Struggle with stubborn fat that does not respond to a conventional diet and exercise Experience weight regain after past dieting attempts Have signs of metabolic slowdown, such as low energy or difficulty building muscle It is also suitable for individuals seeking medically guided, sustainable weight control

During the study, these participants had clear improvements in HbA1c, BMI and HOMA2-B in response to both drugs, with a relatively larger effect of semaglutide

Participants who switched from injectable Wegovy to oral orforglipron maintained their previously achieved weight loss with only a 0.9 kg average difference

As with semaglutide, improvements in delivery of retatrutide and identification of new targets, such as FGF21, could offer even more elegant solutions